Scynexis SCYX
NASDAQ SCYX
$4.91 -0.24 (-4.66%)
At close: Sep 9, 2026 · 4:00 PM EDT

Scynexis (SCYX) Short term Debt (2013 - 2023)

Scynexis' (SCYX) quarterly Short term Debt came in at $34.6 million in Q1 2023, up 371.47% quarter-over-quarter from $7.3 million in Q3 2018.

Analysis

Scynexis (SCYX) Short term Debt (2013 - 2023) Analysis & Trends

Scynexis (SCYX) has reported Short term Debt for 5 consecutive years, with $34.6 million the latest figure, recorded in Q1 2023.

  • For the quarter ending Q1 2023, Short term Debt changed N/A year-over-year to $34.6 million; the trailing twelve-month figure through Mar 2023 stood at $34.6 million (changed N/A YoY), and the FY2017 full-year result was $4.3 million, changed N/A from the prior year.
  • Short term Debt improved to $34.6 million in Q1 2023 per SCYX's latest filing, from $7.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $34.6 million in Q1 2023 and bottomed at $34.6 million in Q1 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Scynexis 58.41 Mn -56.29 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 34.65 Mn
Sep 30, 2018 7.35 Mn
Jun 30, 2018 5.47 Mn
Mar 31, 2018 3.60 Mn
Dec 31, 2017 4.35 Mn
Sep 30, 2017 2.85 Mn
Jun 30, 2017 1.35 Mn
Mar 31, 2014 15.00 Mn
Dec 31, 2013 15.00 Mn